Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018.

ABSTRACT:

Importance

The growth of cancer drug spending in the US has outpaced spending in nearly all other sectors, and an increasing proportion of the drug development pipeline is devoted to oncology. In 2018, there was a record number of drugs entering the US market.

Objective

To estimate the number of patients with cancer who are eligible for the newly approved drug-indication pairs, and project potential spending and use of the approvals in the US.

Design, setting, participants

This is a retrospective review of 2018 US Food and Drug Administration (FDA) oncology drug approvals with estimation of the eligible population. The cost of new therapy was estimated, and savings from displaced therapies were subtracted. Two-way sensitivity analysis explored uncertainty in pricing a

SUBMITTER: DeMartino PC 

PROVIDER: S-EPMC7653539 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature